In a news release, life sciences company Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced that "it has secured a six tonne order of OxC-betaT™ Livestock from Transformadora Agricola de Alimentos S.A. de C.V in Mexico."
The firm stated that this one-year order will be fulfilled in 12 monthly 500 kg shipments beginning in April 2021. Avivagen advised that this is the first order of OxC-beta Livestock it has received from this new customer. The company noted that this order represents its second large order from customers in Mexico in recent months following an order for ten tonnes it received in September 2020 from Industrias Melder. Avivagen indicated that its Mexico-based consultant Meyenberg International Group is credited with securing this latest six tonne OxC-beta Livestock order.
Avivagen's CEO Kym Anthony commented, "We are excited to add a prominent new customer and announce another significant order for OxC-beta™ Livestock in Mexico, a key and growing region for Avivagen...With a number of prospective customers currently running or having completed trials of their own, we anticipate demand for OxC-beta™ Livestock to continue to grow steadily in this increasingly significant region."
The firm stated that Transformadora Agricola de Alimentos is located in Santiago de Queretaro and was established is owned by Raúl Troyo de la Llave, who has been a leading figure in the Mexican industrial agriculture industry for nearly 40 years. The company stated that Mr. Troyo de la Llave is an active and highly influential figure in many important livestock associations across Mexico including the Mexican Association of Food Producers A.C., the Livestock Association of Querétaro and the Querétaro Pig Producers Association.
The company advised that its OxC-beta technology is derived from an overlooked facet of β-carotene and other carotenoid compound discoveries. The firm noted that these compounds which support immune function are what give many fruits and vegetables their bright colors. Avivagen stated that OxC-beta provides a safe, effective, economical and non-antibiotic means of promoting health and growth and that it believes OxC-beta Livestock product could serve to fulfill the global mandate to remove all in-feed antibiotics as growth promoters. The company reported that its OxC-beta Livestock product is approved for use in Australia, Brazil, Malaysia, Mexico, New Zealand, the Philippines, Taiwan, Thailand and the U.S.
Read what other experts are saying about:
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
